HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Swanson, R. A. Search for Related Content PubMed PubMed Citation Articles by Swanson, R. A.

Intravenous heparin for acute stroke

What can we learn from the megatrials?

From the Cerebrovascular Research Group, Neurology Service, VAMC San Francisco, and University of California, San Francisco, CA.

Address correspondence and reprint requests to Dr. Raymond A. Swanson, (127) Neurology, V.A.M.C., 4150 Clement St., San Francisco, CA 94121.

Article Abstract

Recently published large clinical trials of heparin and aspirin in acute stroke—the International Stroke Trial, Chinese Acute Stroke Trial, and Trial of ORG 10172 in Acute Stroke Treatment—fail to show a net benefit from heparin. None of these trials used IV, dose-adjusted, unfractionated heparin as generally employed in the United States. However, the control groups in these trials provide data on acute stroke recurrence in large numbers of patients, and these stroke recurrence rates can be used to establish an upper limit for the potential efficacy of antithrombotic therapy. The rates of recurrent ischemic stroke in the control groups of these trials were low, ranging from 0.6 to 2.2% per week. The low rates of recurrent stroke observed in these groups, coupled with the morbidity and mortality associated with IV heparin in this patient population, argue against routine use of IV heparin in the acute stroke period.

This article has been cited by other articles:

				G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 630S - 669S. [Abstract] [Full Text] [PDF]

				G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 483S - 512S. [Abstract] [Full Text] [PDF]

				M. Moonis and M. Fisher Considering the Role of Heparin and Low-Molecular-Weight Heparins in Acute Ischemic Stroke Stroke, July 1, 2002; 33(7): 1927 - 1933. [Abstract] [Full Text] [PDF]

				A. Al-Sadat, M. Sunbulli, and S. Chaturvedi Use of Intravenous Heparin by North American Neurologists: Do the Data Matter? Stroke, June 1, 2002; 33(6): 1574 - 1577. [Abstract] [Full Text] [PDF]

				H. P. Adams Jr Emergent Use of Anticoagulation for Treatment of Patients With Ischemic Stroke Stroke, March 1, 2002; 33(3): 856 - 861. [Abstract] [Full Text] [PDF]

				G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Chest, January 1, 2001; 119(1_suppl): 300S - 320S. [Full Text] [PDF]

				C. J. Estol and R. A. Swanson Intravenous heparin for acute stroke: What can we learn from the megatrials? Neurology, April 11, 2000; 54(7): 1542 - 1546. [Full Text] [PDF]